1073371-99-9

Basic information

• Product Name: 3-HYDROXY-4-METHOXYCARBONYLPHENYLBORONIC ACID, PINACOL ESTER
• Synonyms: 3-HYDROXY-4-METHOXYCARBONYLPHENYLBORONIC ACID, PINACOL ESTER;Methyl 2-hydroxy-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzoate
• CAS NO: 1073371-99-9
• Molecular Formula: C₁₄H₁₉BO₅
• Molecular Weight: 278.11
• Mol File: 1073371-99-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 383.9±32.0 °C(Predicted)
• Appearance: /
• Density: 1.17±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 9.80±0.10(Predicted)
• CAS DataBase Reference: 3-HYDROXY-4-METHOXYCARBONYLPHENYLBORONIC ACID, PINACOL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-HYDROXY-4-METHOXYCARBONYLPHENYLBORONIC ACID, PINACOL ESTER(1073371-99-9)
• EPA Substance Registry System: 3-HYDROXY-4-METHOXYCARBONYLPHENYLBORONIC ACID, PINACOL ESTER(1073371-99-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 1073371-99-9(Hazardous Substances Data)

Usage

Uses

3-Hydroxy-4-methoxycarbonylphenylboronic acid, pinacol ester

Upstream product

• 18179-39-0 methyl 4-iodosalicylate 
• 73183-34-3 bis(pinacol)diborane 
• 149878-72-8 2-hydroxy-4-trifluoromethanesulfonyloxybenzoic acid methyl ester 
• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 89-86-1 4-hydroxysalicylic acid 
• 22717-56-2 4-bromo-2-Hydroxybenzoic Acid Methylester 

Downstream Products

• 1429313-07-4 methyl 4-[5-(2,2,3,3,13,13-hexamethyl-11-oxo-4,7,12-trioxa-10-aza-3-silatetradecan-10-yl)pyrazolo[1,5-a]pyrimidin-3-yl]-2-hydroxybenzoate 
• 1429313-08-5 methyl 4-(5-{[(tert-butoxy)carbonyl][2-(2-hydroxyethoxy)ethyl]amino}pyrazolo[1,5-a]pyrimidin-3-yl)-2-hydroxybenzoate 
• 1429313-23-4 C₂₈H₃₇N₅O₈ 
• 1429313-22-3 C₃₄H₅₁N₅O₈Si 
• 1374263-36-1 methyl 4-[3-(4-{1-[(tert-butoxycarbonyl)amino]cyclobutyl}phenyl)-9H-imidazo[1,2-d]pyrido[2,3-b][1,4]benzodiazepin-2-yl]-2-hydroxybenzoate 

Relevant articles and documents

Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor

Casein kinase 2 (CK2) is a constitutively expressed serine/threonine kinase that has a large diversity of cellular substrates. Thus, CK2 has been associated with a plethora of regulatory functions and dysregulation of CK2 has been linked to disease development in particular to cancer. The broad implications in disease pathology makes CK2 an attractive target. To date, the most advanced CK2 inhibitor is silmitasertib, which has been investigated in clinical trials for treatment of various cancers, albeit several off-targets for silmitasertib have been described. To ascertain the role of CK2 inhibition in cancer, other disease and normal physiology the development of a selective CK2 inhibitor would be highly desirable. In this study we explored the pyrazolo [1,5-a]pyrimidine hinge-binding moiety for the development of selective CK2 inhibitors. Optimization of this scaffold, which included macrocyclization, led to IC20 (31) a compound that displayed high in vitro potency for CK2 (KD = 12 nM) and exclusive selectivity for CK2. X-ray analysis revealed a canonical type-I binding mode for IC20 (31). However, the polar carboxylic acid moiety that is shared by many CK2 inhibitors including silmitasertib was required for potency but limits the cellular activity of IC20 (31) and the cellular IC50 dropped to the low micromolar range. In summary, IC20 (31) represents a highly selective and potent inhibitor of CK2, which can be used as a tool compound to study CK2 biology and potential new applications for the treatment of diseases.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula (I): wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

METAL ORGANIC FRAMEWORKS COMPRISING A PLURALITY OF SBUS WITH DIFFERENT METAL IONS AND/OR A PLURALITY OF ORGANIC LINKING LIGANDS WITH DIFFERENT FUNCTIONAL GROUPS.

The disclosure provides for metal organic frameworks (MOFs) which comprise a plurality of SBUs comprising different metals or metal ions and/or a plurality of organic linking moieties comprising different functional groups.